UK authorities also concluded the benefits outweighed the risks in most age groups, but presented data that showed the benefits to people under 30 only slightly outweighed the risks in scenarios where exposure to the virus is limited. Those who had already received the first AstraZeneca shot, however, should be offered the second, they said.
EMA's findings and the UK's new advice also follow a move in Germany, which last week suspended the use of the AstraZeneca vaccine in people under 60 years old after 31 reports of CVST. Twenty-nine of the 31 were women aged 20 to 63, and nine of the patients died, according to a Reuters report citing the country's medicines regulator.
Cooke said there was no clear risk profile found when the safety committee looked at the age and *** of people reporting these rare adverse reactions, even though a statement published by EMA earlier made clear
most of the cases reported "occurred in women under 60 years of age within 2 weeks of vaccination."